DRIEHAUS CAPITAL MANAGEMENT
Driehaus is an investment management firm that manages growth equity investment strategies and multi-asset alternative strategies. The firm has a diverse institutional client base comprised of corporate and public pensions, endowments, foundations, sub-advisory, family offices, wealth managers, and financial advisors, globally. Driehaus is a performance-oriented investment management boutique that emphasizes integrity, transparency, and the alignment of the firm’s interests with its clients. The firm was founded in 1982 and is headquartered in Chicago, Illinois.
DRIEHAUS CAPITAL MANAGEMENT
Industry:
Finance Financial Services Management Consulting
Founded:
1982-01-01
Status:
Active
Contact:
(312) 587-3800
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Apache Microsoft Exchange Online Amazon
Similar Organizations
Techstars Ventures
Techstars Ventures is a venture capital firm that empowers entrepreneurs to bring new technologies to the market.
Par Mais
Par Mais is an investment and asset management that aims to change the relationship between people and money.
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-08 | Annexon Biosciences | Driehaus Capital Management investment in Post-IPO Equity - Annexon Biosciences | 130 M USD |
| 2022-02-08 | Congruence Therapeutics | Driehaus Capital Management investment in Series A - Congruence Therapeutics | 63 M CAD |
| 2022-01-10 | Maze Therapeutics | Driehaus Capital Management investment in Venture Round - Maze Therapeutics | 190 M USD |
| 2021-08-24 | Dice Therapeutics | Driehaus Capital Management investment in Series C - Dice Therapeutics | 60 M USD |
| 2021-07-19 | Frontier Medicines | Driehaus Capital Management investment in Series B - Frontier Medicines | 88.5 M USD |
| 2021-05-11 | Nuvalent | Driehaus Capital Management investment in Series B - Nuvalent | 135 M USD |
| 2021-05-05 | NeoGenomics | Driehaus Capital Management investment in Post-IPO Equity - NeoGenomics | 200 M USD |
| 2021-04-15 | C2i Genomics | Driehaus Capital Management investment in Series B - C2i Genomics | 100 M USD |
| 2021-04-12 | Crinetics Pharmaceuticals | Driehaus Capital Management investment in Post-IPO Equity - Crinetics Pharmaceuticals | 75 M USD |
| 2021-03-19 | X4 Pharmaceuticals | Driehaus Capital Management investment in Post-IPO Equity - X4 Pharmaceuticals | 55 M USD |